0000899243-20-015868.txt : 20200609 0000899243-20-015868.hdr.sgml : 20200609 20200609202256 ACCESSION NUMBER: 0000899243-20-015868 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200608 FILED AS OF DATE: 20200609 DATE AS OF CHANGE: 20200609 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Satter Muneer A CENTRAL INDEX KEY: 0001315797 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38130 FILM NUMBER: 20953271 MAIL ADDRESS: STREET 1: C/O SATTER INVESTMENT MANAGEMENT, LLC STREET 2: 676 NORTH MICHIGAN AVENUE, SUITE 4000 CITY: CHICAGO STATE: IL ZIP: 60611 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AILERON THERAPEUTICS INC CENTRAL INDEX KEY: 0001420565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 490 ARSENAL WAY CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-995-0900 MAIL ADDRESS: STREET 1: 490 ARSENAL WAY CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-08 0 0001420565 AILERON THERAPEUTICS INC ALRN 0001315797 Satter Muneer A C/O SATTER MANAGEMENT CO., L.P., 676 NORTH MICHIGAN AVENUE, SUITE 4000 CHICAGO IL 60611 1 0 1 1 See Remarks Common Stock 2020-06-08 4 P 0 3700000 1.10 A 7609449 I See Footnote Reflects shares that were purchased directly from the underwriter in an underwritten public offering conducted by the Issuer. The amount in Column 4 includes (a) 350,742 shares purchased by various trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares and (b) 3,349,258 shares purchased by Satter Medical Technology Partners, L.P. ("SMTP") for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (a) and (b) of this footnote (1), except to the extent of his pecuniary interest. The amount in Column 5 includes (a) 161,440 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 367,408 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by SMTP for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (2), except to the extent of his pecuniary interest therein. In connection with its original investment, SMTP had a contractual right to designate one member of the Board of Directors of Aileron Therapeutics, Inc. Therefore, the Reporting Person may be deemed to be a director by deputization. /s/ Robert M. Hayward, P.C., attorney-in-fact for Muneer Satter 2020-06-09